Beta-blocker prophylaxis for atrial fibrillation after coronary artery bypass grafting in patients with sympathovagal imbalance

Ann Thorac Surg. 2007 Jul;84(1):61-6. doi: 10.1016/j.athoracsur.2007.02.014.

Abstract

Background: Atrial fibrillation (AF) is the most common arrhythmia after coronary bypass grafting (CABG) resulting in a prolonged hospital stay and higher costs. The withdrawal of beta-blocker and a sympathovagal imbalance were identified as risk factors for AF.

Methods: In our study we performed a measuring of standard deviation of all normal RR intervals (SDNN) among 142 consecutive patients with beta-blocker therapy before CABG in order to identify a collective who had an increased risk due to a withdrawal of beta-blocker medication. A sympathovagal imbalance was predefined as a SDNN below 30 ms. Patients were divided into four groups according to the results of SDNN and the continuous beta-blocker therapy: group I: SDNN < or = 30 ms or less and withdrawal of beta-blocker therapy (26 patients); group II: SDNN < or = 30 ms and continuously beta-blocker therapy (33 patients); group III: SDNN > 30 ms and withdrawal of beta-blocker therapy (40 patients); group IV: SDNN > 30 ms and continuous beta-blocker therapy (43 patients).

Results: Atrial fibrillation occurred in 39 patients (27%) after surgery. Patients of group I showed a higher incidence of AF (14 of 26 patients, 54%) than patients of group II (7 of 33 patients, 21%; p < 0.009), patients of group III (8 of 40 patients, 20%; p < 0.004), or patients of group IV (10 of 43 patients, 23%; p < 0.01). We found a significantly higher incidence of diabetes mellitus (47 vs 14% of patients; p < 0.0001) in patients with a sympathovagal imbalance than patients with a SDNN above 30 ms.

Conclusions: The results of our study suggest a sympathovagal imbalance and withdrawal of a beta-blocker therapy increase the risk of postoperative AF. A continuous beta-blocker therapy reduces the risk especially in patients with a sympathovagal imbalance and should always be practiced.

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Aged
  • Atrial Fibrillation / prevention & control*
  • Coronary Artery Bypass / adverse effects*
  • Diabetes Mellitus / physiopathology
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Sympathetic Nervous System / physiopathology*
  • Vagus Nerve / physiopathology*

Substances

  • Adrenergic beta-Antagonists